Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by Clarius Group LLC

Clarius Group LLC trimmed its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 10.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 368,995 shares of the company's stock after selling 41,000 shares during the period. Clarius Group LLC owned about 0.25% of Denali Therapeutics worth $5,016,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of DNLI. Vanguard Group Inc. boosted its position in Denali Therapeutics by 7.6% during the fourth quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock worth $244,993,000 after acquiring an additional 843,996 shares during the last quarter. FMR LLC grew its stake in shares of Denali Therapeutics by 2.4% during the 4th quarter. FMR LLC now owns 8,019,746 shares of the company's stock valued at $163,442,000 after buying an additional 188,368 shares during the period. Alliancebernstein L.P. increased its holdings in shares of Denali Therapeutics by 8.8% during the 4th quarter. Alliancebernstein L.P. now owns 3,315,642 shares of the company's stock worth $67,573,000 after buying an additional 268,378 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Denali Therapeutics by 6.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,058,615 shares of the company's stock worth $62,335,000 after buying an additional 188,820 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Denali Therapeutics by 19.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,855,036 shares of the company's stock worth $37,805,000 after buying an additional 295,594 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI traded down $0.29 during midday trading on Friday, reaching $13.80. The company had a trading volume of 410,287 shares, compared to its average volume of 1,131,093. Denali Therapeutics Inc. has a one year low of $10.57 and a one year high of $33.33. The stock has a market capitalization of $2.00 billion, a P/E ratio of -5.16 and a beta of 1.32. The stock's fifty day moving average price is $14.30 and its 200-day moving average price is $17.55.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same quarter last year, the business posted ($0.68) EPS. As a group, sell-side analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on DNLI shares. Robert W. Baird dropped their price target on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a research note on Thursday, May 8th. Morgan Stanley began coverage on shares of Denali Therapeutics in a research report on Friday, March 7th. They set an "overweight" rating and a $33.00 target price for the company. Cantor Fitzgerald upgraded shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a report on Thursday, April 10th. Wedbush decreased their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Finally, Oppenheimer dropped their price objective on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $33.71.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.